Literature DB >> 10417182

Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide.

Z Zhong1, T Burns, Q Chang, M Carroll, L Pirofski.   

Abstract

The structural characteristics and biological activity of human antibodies that are reactive with the capsular polysaccharides of most serotypes of Streptococcus pneumoniae, including serotype 8, are unknown. This paper describes the generation, molecular structure, and protective efficacy of a human monoclonal antibody (MAb) reactive with the capsular polysaccharide of serotype 8 Streptococcus pneumoniae. We generated the immunoglobulin M(kappa) [IgM(kappa)] MAb D11 by Epstein-Barr virus transformation of peripheral lymphocytes from a Pneumovax recipient. Nucleic acid sequence analysis revealed that MAb D11 uses V3-15/V(H)3 and A20/V(kappa) gene segments with evidence of somatic mutation. In vitro studies revealed MAb D11-dependent complement deposition on the capsule of serotype 8 organisms via either the classical or the alternative complement pathway. In vivo, MAb D11 prolonged the survival of both normal and C4-deficient mice with lethal serotype 8 S. pneumoniae infection. Our findings demonstrate that a serotype-specific human IgM with certain structural and functional characteristics was protective in mice lacking a functional classical complement pathway and show that alternative complement pathway activation is an important determinant of pneumococcal protection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417182      PMCID: PMC96715     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

Review 2.  Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?

Authors:  L A Pirofski; A Casadevall
Journal:  Zentralbl Bakteriol       Date:  1996-08

3.  Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway.

Authors:  C Suankratay; X H Zhang; Y Zhang; T F Lint; H Gewurz
Journal:  J Immunol       Date:  1998-03-15       Impact factor: 5.422

4.  Regulation of the B cell response to T-dependent antigens by classical pathway complement.

Authors:  M B Fischer; M Ma; S Goerg; X Zhou; J Xia; O Finco; S Han; G Kelsoe; R G Howard; T L Rothstein; E Kremmer; F S Rosen; M C Carroll
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

5.  Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.

Authors:  A M Stack; R Malley; C M Thompson; L Kobzik; G R Siber; R A Saladino
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

6.  Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.

Authors:  N P Steele; R S Munson; D M Granoff; J E Cummins; R P Levine
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

7.  The critical role of complement in experimental pneumococcal sepsis.

Authors:  S W Hosea; E J Brown; M M Frank
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

8.  Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes.

Authors:  P C Wilson; O de Bouteiller; Y J Liu; K Potter; J Banchereau; J D Capra; V Pascual
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307

9.  The human mannose-binding protein functions as an opsonin.

Authors:  M Kuhlman; K Joiner; R A Ezekowitz
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

10.  The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.

Authors:  F Matsuda; K Ishii; P Bourvagnet; K i Kuma; H Hayashida; T Miyata; T Honjo
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  26 in total

1.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  In vitro antibacterial effects of antilipopolysaccharide DNA aptamer-C1qrs complexes.

Authors:  J G Bruno; M P Carrillo; T Phillips
Journal:  Folia Microbiol (Praha)       Date:  2008-08-31       Impact factor: 2.099

5.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

6.  Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.

Authors:  Tamika Burns; Maria Abadi; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Natural human antibodies to pneumococcus have distinctive molecular characteristics and protect against pneumococcal disease.

Authors:  H E Baxendale; M Johnson; R C M Stephens; J Yuste; N Klein; J S Brown; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

9.  Feasibility of radioimmunotherapy of experimental pneumococcal infection.

Authors:  E Dadachova; T Burns; R A Bryan; C Apostolidis; M W Brechbiel; J D Nosanchuk; A Casadevall; L Pirofski
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.